The levonorgestrel IUS (Mirena) is one of the most-studied hormonal treatments for endo, particularly effective for patients who also have adenomyosis. A 2022 meta-analysis of 71 RCTs found strong pain reduction in adenomyosis; for endo specifically it's comparable to oral progestins or COCPs but with dramatically better real-world adherence — 91.5% of users continued treatment beyond 5 years versus 21.9% on oral options. Two recent safety signals warrant informed discussion: a 2025 Korean cohort (n=61,010) found a 38% increased breast cancer risk, and a 2024 Danish cohort (n=149,200) found a dose-dependent increased depression risk. A 2025 study found no increased kidney disease risk.
Research status
Well Studied
Endo-specific
Yes
Community signal
Mixed
How does Mirena IUD work?
The LNG-IUS releases levonorgestrel (a synthetic progestin) directly into the uterus at a steady low dose (initially ~20 mcg/day for Mirena 52mg, declining over 5-8 years). Mechanisms in endometriosis: (1) Local suppression of endometrial proliferation — the endometrium becomes atrophic, reducing menstrual bleeding substantially and often stopping periods entirely; (2) Direct action on endometriotic lesions via progesterone receptor activation, inhibiting proliferation and promoting decidualisation; (3) Reduced retrograde menstruation (less menstrual tissue means less material reaching the peritoneum); (4) Local anti-inflammatory effects via reduced prostaglandin production; (5) Possibly reduced uterine contractility contributing to reduced dysmenorrhoea. The local delivery is key — systemic levonorgestrel levels are much lower than with oral contraceptives, which is why systemic side effects (mood changes, weight, nausea) are generally milder than with oral progestins. However, the recently identified breast cancer and depression signals suggest systemic absorption is meaningful enough to matter clinically.
What does the research show about Mirena IUD for endometriosis?
Below are studies linked to this intervention in our database, with design, quality, and outcomes summarised for quick scanning. Endo-specific evidence in this entry: Yes.
15 studies
Hormonal Treatment of Endometriosis: A Narrative Review
Piriyev E, Schiermeier S & Römer T · 2025
Systematic reviewEndometriosis-specificQuality: Medium
Narrative review of hormonal treatments for endo. States LNG-IUS is "especially effective in patients with adenomyosis". Progestins (particularly dienogest) noted as most suitable long-term hormonal option overall. GnRH agonists/antagonists reserved for second-line due to hypo-oestrogenic side effects. Positions LNG-IUS appropriately within contemporary hormonal treatment landscape.
Hormonal Treatment of Endometriosis: A Narrative Review
Piriyev E, Schiermeier S & Römer T · 2025
Systematic reviewEndometriosis-specificQuality: Medium
Narrative review of hormonal treatments for endo. States LNG-IUS is "especially effective in patients with adenomyosis". Progestins (particularly dienogest) noted as most suitable long-term hormonal option overall. GnRH agonists/antagonists reserved for second-line due to hypo-oestrogenic side effects. Positions LNG-IUS appropriately within contemporary hormonal treatment landscape.
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence
Yuk JS et al. · 2025
Observationaln=61,010Not endo-specificQuality: High
Korean nationwide retrospective cohort study using National Health Insurance Claims database 2013-2022. 61,010 women aged 30-49 with endometriosis, fibroids, or abnormal uterine bleeding. Propensity-matched analysis. Breast cancer incidence: 223 per 100,000 person-years in LNG-IUS users vs 154 in non-users. LNG-IUS use associated with increased breast cancer risk (HR 1.38, 95% CI 1.19-1.59). Risk particularly elevated in first 3 years of use (early-initiator HR up to 5.40). Important safety signal for informed consent.
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence
Yuk JS et al. · 2025
Observationaln=61,010Not endo-specificQuality: High
Korean nationwide retrospective cohort study using National Health Insurance Claims database 2013-2022. 61,010 women aged 30-49 with endometriosis, fibroids, or abnormal uterine bleeding. Propensity-matched analysis. Breast cancer incidence: 223 per 100,000 person-years in LNG-IUS users vs 154 in non-users. LNG-IUS use associated with increased breast cancer risk (HR 1.38, 95% CI 1.19-1.59). Risk particularly elevated in first 3 years of use (early-initiator HR up to 5.40). Important safety signal for informed consent.
Association of levonorgestrel intrauterine system and chronic kidney disease: A nationwide population-based cohort study
Park Y et al. · 2025
Observationaln=1,226,843Not endo-specificQuality: High
Korean nationwide cohort of 1.2 million women aged 30-49 with endometriosis, fibroids, or abnormal uterine bleeding (2014-2017). 33,822 LNG-IUS users vs 1,193,021 non-users. LNG-IUS NOT associated with increased CKD risk (HR 0.967, 95% CI 0.704-1.328, p=0.836) after adjusting for multiple confounders. Reassuring safety data for long-term use.
Association of levonorgestrel intrauterine system and chronic kidney disease: A nationwide population-based cohort study
Park Y et al. · 2025
Observationaln=1,226,843Not endo-specificQuality: High
Korean nationwide cohort of 1.2 million women aged 30-49 with endometriosis, fibroids, or abnormal uterine bleeding (2014-2017). 33,822 LNG-IUS users vs 1,193,021 non-users. LNG-IUS NOT associated with increased CKD risk (HR 0.967, 95% CI 0.704-1.328, p=0.836) after adjusting for multiple confounders. Reassuring safety data for long-term use.
Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis
Oliveira JA et al. · 2025
Meta-analysisn=1,503Not endo-specificQuality: High
SR+MA of 6 RCTs (n=1,503) comparing LNG-IUS vs subdermal implants (etonogestrel). LNG-IUS had lower rates of dissatisfaction (OR 2.42 for implants), acne (OR 2.21), weight gain (OR 4.63), and device removal due to side effects (OR 2.02). Important comparative tolerability data for women considering long-acting progestin options for endo management.
Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis
Oliveira JA et al. · 2025
Meta-analysisn=1,503Not endo-specificQuality: High
SR+MA of 6 RCTs (n=1,503) comparing LNG-IUS vs subdermal implants (etonogestrel). LNG-IUS had lower rates of dissatisfaction (OR 2.42 for implants), acne (OR 2.21), weight gain (OR 4.63), and device removal due to side effects (OR 2.02). Important comparative tolerability data for women considering long-acting progestin options for endo management.
Long acting progestogens versus combined oral contraceptive pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open label, randomised controlled trial
Cooper et al. · 2024
RCTn=405Endometriosis-specificQuality: High
UK pragmatic RCT in 34 hospitals. Long-acting progestins (Mirena or DMPA injection) vs COCP after surgery. At 3 years, both groups had similar ~40% pain improvement, but progestin group had fewer repeat surgeries (HR 0.67). Strong support for Mirena as first-line post-surgical option.
Long acting progestogens versus combined oral contraceptive pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open label, randomised controlled trial
Cooper et al. · 2024
RCTn=405Endometriosis-specificQuality: High
UK pragmatic RCT in 34 hospitals. Long-acting progestins (Mirena or DMPA injection) vs COCP after surgery. At 3 years, both groups had similar ~40% pain improvement, but progestin group had fewer repeat surgeries (HR 0.67). Strong support for Mirena as first-line post-surgical option.
What do people in online endo communities say about Mirena IUD?
Community signals are indicative only — they reflect informal conversation in endometriosis-focused spaces. People posting may or may not have a formal diagnosis; this is not a substitute for clinical evidence or care.
Reddit
Mixed · 6,000 mentions
HealthUnlocked
Mixed · 2,800 mentions
“Best decision I ever made for my endo, but the first 4 months were rough. Spotting constantly, mood all over the place. Now at 18 months — no periods, pain way down, would do it again.”
— Reddit
“Insertion was honestly traumatic. Wasn't offered any pain relief beyond paracetamol. Please ask for sedation or local anaesthetic, don't be brave.”
— Reddit
“Got it removed after 8 months. The depression and acne weren't worth it for me, even though the pain was better. Going back on dienogest.”
— Reddit
“Game changer for me. Period gone, pain massively reduced, came off pills that weren't working. Side effects in first 6 months but worth it.”
— HealthUnlocked
“I had three insertion attempts before it went in successfully. Whole experience put me off. Take pain relief seriously and consider sedation if you can access it.”
— HealthUnlocked
“Mirena + low-dose oestrogen patch is what finally worked for me. The progestin alone was making me too low mood, the patch evened things out.”
— HealthUnlocked
How is Mirena IUD typically used?
Practical notes
Insertion is a clinic procedure, typically uncomfortable (sometimes severely painful) — ask about pain management options before. Takes 5-15 minutes. Cramping and irregular bleeding are common for 3-6 months after insertion and usually settle. Most users develop much lighter periods or stop bleeding altogether. Effective for 5-8 years depending on brand (Mirena 52mg: 8 years for contraception, 5 years for heavy bleeding/endo). Best-supported uses include post-surgical maintenance therapy (91.5% adherence at 5 years per Kim 2022 — much better than oral options), management of coexisting adenomyosis (where evidence is strongest), and as a second-line option after COCPs or dienogest. Contraindications include current or past breast cancer, active pelvic infection, unexplained uterine bleeding, and distorted uterine cavity. Can be removed at any time, fertility returns quickly after removal. Cost: ~£100-200 privately in UK; free on NHS. Valid for contraception, heavy menstrual bleeding, and endometriosis-associated pain.
What should you know before trying Mirena IUD?
Two significant safety signals have emerged from large-population studies that should be part of informed consent: (1) Yuk 2025 (n=61,010 Korean retrospective cohort) found LNG-IUS associated with a 38% increased breast cancer risk (HR 1.38, 95% CI 1.19-1.59), with risk particularly elevated during the first 3 years of use (early-initiator HR up to 5.40). (2) Larsen 2024 (n=149,200 Danish cohort) found a dose-dependent increased risk of incident depression, with high-dose LNG-IUS users showing 52% higher risk than low-dose users. These are observational studies and causality is uncertain, but the dose-response relationship in the depression data is concerning. Other considerations: higher rate of irregular bleeding vs oral options (Wang 2022: 26.8% vs 0% in comparison trials); expulsion rate 2-5%; rare but serious uterine perforation at insertion (~1 in 1000); risk of device displacement. Reassuring: Park 2025 (n=1.2M Korean cohort) found no association with chronic kidney disease, and comparison with subdermal implants (Oliveira 2025 MA) showed LNG-IUS is better tolerated in several metrics (lower acne, weight gain, and removal due to side effects).
Related interventions
Other interventions in our database that target similar symptoms or fall under the same category as Mirena IUD.